Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 booster study of IVX-411 with or without MF59 in previously vaccinated adults
ACTRN12621000882820Phase 2Completed
- Sponsor
- Icosavax, Inc.
- Start
- Sep 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of IVX-411 in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Icosavax, Inc. Primary endpoints: Solicited local and systemic adverse events, Unsolicited adverse events and 1 more. Started Sep 2021; status: completed.
02
Drugs
IVX-411
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621000882820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000882820.